Very few state laws require a pharmacy to use a drug container that meets minimum quality-control standards. Legal metrics are needed to guard against possible patient harm resulting from an adulterated drug product caused by a "bad" container.
For pharmacies in the compounding business, an attractive, centrally located clean room that is visible to patients will generate substantial return on investment, propel business growth, and market the pharmacy as an innovator.
Until recently, none of our education systems has been preparing healthcare professionals for teamwork. That is beginning to change. While more remains to be done, we must look to a future characterized by high-functioning interprofessional teams in all practice settings.
Chief executives from key pharmacy organizations met in mid-2010 to reinforce the joint message that the fight to move pharmacy into a central healthcare role has just begun.
There are 2 measures of success every pharmacy should post on its wall. The first indicates percentage of QREs (quality-related events) in prescription fills, and the second measures the percentage of QREs caught before they reach the patient.
Controlling the expensive price tag of Medicare is an ongoing concern of both the Obama administration and Congress. Therefore, any Medicare provider can expect an audit. Is your pharmacy prepared?
In 10 of its Chicago-area stores, Walgreens is piloting a program to provide healthy food options such as fresh fruits and vegetables, frozen meats and fish, eggs, and whole-grain cereals and pastas in its stores.
The Department of Veteran Affairs is partnering with the Indian Health Services to improve prescription delivery to the federally recognized tribes of IHS, a population of about 2 million people.
Under the federal Controlled Substances Act, marijuana is classified as Schedule I, a definition that gives it a high potential for abuse, with no current safe or medical use. Meanwhile, in 14 states, patients have access to medical marijuana upon physican recommendation.
While there may be some notable breakthroughs to brighten an otherwise bleak pharmaceutical pipeline for 2011, the overall outlook remains grim as the number of new drugs under development continues to shrink, compared to the glory days of just a few short years ago.